ReviewClinical medicine insights. Ear, nose and throat2019
Mucoactive Agents in the Therapy of Upper Respiratory Airways Infections: Fair to Describe Them Just as Mucoactive?
Review in Clinical medicine insights. Ear, nose and throat, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 47 citations in OpenAlex.
- Efficacy and safety of inhaled ambroxol solution in improving sputum of lower respiratory tract infection in children: a multicenter, randomized, double-blind, placebo-controlled trial.BMC pulmonary medicine · 2025Trial
- Efficacy of Bromhexine hydrochloride combined with bronchoalveolar lavage under fiberoptic bronchoscopy in the treatment of mild to moderate community-acquired pneumonia.Pakistan journal of medical sciences · 2026Article
- Association of Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution with Respiratory Symptom Improvement and Safety in Chinese Children with Pneumonia: A Real-World Propensity Score-Matched Study.Infection and drug resistance · 2026Article
- Site-Specific Microparticle Inhalation Therapy: A New Approach to Nasopharyngeal Symptoms.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Investigation into the Effectiveness of an Herbal Combination (AngocinAntibiotics (Basel, Switzerland) · 2024Article
- Sobrerol in Managing Acute Respiratory Infections in Clinical Practice During the "Cold" Season: An Italian Primary Care Experience.International journal of general medicine · 2024Article
- Sobrerol: New Perspectives to Manage Patients with Frequent Respiratory Infections.Children (Basel, Switzerland) · 2023Review
- Rhinosinusitis: clinical-based phenotyping.Acta bio-medica : Atenei Parmensis · 2022Article
- Design of Oral Sustained-Release Pellets by Modeling and Simulation Approach to Improve Compliance for Repurposing Sobrerol.Pharmaceutics · 2022Article
- Survey of potentially inappropriate prescriptions for common cold symptoms in Japan: A cross-sectional study.PloS one · 2022Article
- Network pharmacology reveals multitarget mechanism of action of drugs to be repurposed for COVID-19.Frontiers in pharmacology · 2022Article
- Pharmacist's recommendations of over-the-counter treatments for the common cold - analysis of prospective cases in Poland.BMC family practice · 2021Article
- Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges.Molecular biology reports · 2021Review
- Fixed drug eruption and anaphylaxis induced concurrently by erdosteine: a case report.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2021Article
- Comparative in vitro analysis of inhibition of rhinovirus and influenza virus replication by mucoactive secretolytic agents and plant extracts.BMC complementary medicine and therapies · 2020Article
- Status of peripheral sodium channel blockers for non-addictive pain treatment.Nature reviews. Neurology · 2020Review
- Pharmacological treatments of COVID-19.Pharmacological reports : PR · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUpper and lower respiratory tract infections are common conditions for which medical advice is sought, and their management relies on the use of prescription and over-the-counter (OTC) medicines. Ambroxol, bromhexine, carbocysteine, erdosteine,
objectiveTo briefly review the evidence-based efficacy and safety of these substances in the therapy of upper respiratory airways infections.
methodsWe conducted searches in MEDLINE and other databases for clinical trials and reviews done on the efficacy and safety of ambroxol, bromhexine, carbocysteine, erdosteine, NAC, and sobrerol.
resultsClinical trials have shown that these mucolytics have an important place in the relief of cough symptoms by easing the elimination of mucus. All drugs have shown comparable efficacy in the symptomatic treatment of productive cough, with some shared characteristics and some specific features. CONCLUSIONS AND RELEVANCE: All mucolytics reviewed have a good safety profile, although some precautions should be taken when using ambroxol and bromhexine, and the use of NAC and carbocysteine should be monitored in special patient groups. Overall, however, the available evidence from randomised, controlled, and observational trials, as well as pragmatic, real-life experience, suggests that these products are useful in the therapy of upper respiratory airways infections, including bronchitis, sinusitis, and rhinosinusitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.